Evidence map›Paper›PMID 25811188›Full record

ArticlePloS one2015

Elevated NT-pro-brain natriuretic peptide level is independently associated with all-cause mortality in HIV-infected women in the early and recent HAART eras in the Women's Interagency HIV Study cohort.

Matthew R Gingo, Yingze Zhang, Kidane B Ghebrehawariat, Jong-Hyeon Jeong, Yanxia Chu, Quanwei Yang, Lorrie Lucht, David B Hanna, Jason M Lazar, Mark T Gladwin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Matthew R GingoDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Yingze ZhangDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Kidane B GhebrehawariatDepartment of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States of America.
Jong-Hyeon JeongDepartment of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States of America.
Yanxia ChuDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Quanwei YangDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Lorrie LuchtDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
David B HannaDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States of America.
Jason M LazarDepartment of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States of America.
Mark T GladwinDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America; Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh and UPMC, Pittsburgh, PA, United States of America.
Alison MorrisDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
University of Pittsburgh · USAlbert Einstein College of Medicine · USSUNY Downstate Health Sciences University · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIVA, SRUTI · 2011 to 2020
$26.1M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
UAB-MISS WIHS CohortU01AI103401 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KEMPF, MIRJAM-COLETTE, KONKLE-PARKER, DEBORAH J · 2013 to 2018
$11.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1-TR000004NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1-TR000454NHLBI NIH HHS K23 HL108697NHLBI NIH HHS K24 HL123342NHLBI NIH HHS P01 HL103455NHLBI NIH HHS R01 HL090339NHLBI NIH HHS R01 HL126543NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01-AI-034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01-AI-034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01-AI-035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01-AI-103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01-AI-103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01-AI-103401NIAID NIH HHS U01 AI103408NIAID NIH HHS U01-AI-103408NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-032632
6 · The paper itself

Abstract

backgroundHIV-infected individuals are at increased risk of right and left heart dysfunction. N-terminal-pro-brain natriuretic peptide (NT-proBNP), a marker of cardiac ventricular strain and systolic dysfunction, may be associated with all-cause mortality in HIV-infected women. The aim of this study was to determine if elevated levels of NT-proBNP is associated with increased mortality in HIV-infected women.

designProspective cohort study. METHODS AND

resultsWe measured NT-proBNP in 936 HIV-infected and 387 age-matched HIV-uninfected women early (10/11/94 to 7/17/97) and 1082 HIV-infected and 448 HIV-uninfected women late (4/1/08 to 10/7/08) in the highly active antiretroviral therapy (HAART) periods in the Women's Interagency HIV Study. An NT-proBNP >75th percentile was more likely in HIV-infected persons, but only statistically significant in the late period (27% vs. 21%, unadjusted p = 0.03). In HIV-infected participants, NT-proBNP>75th percentile was independently associated with worse 5-year survival in the early HAART period (HR 1.8, 95% CI 1.3-2.4, p<0.001) and remained a predictor of mortality in the late HAART period (HR 2.8, 95% CI 1.4-5.5, p = 0.002) independent of other established risk covariates (age, race/ethnicity, body mass index, smoking, hepatitis C serostatus, hypertension, renal function, and hemoglobin). NT-proBNP level was not associated with mortality in HIV-uninfected women.

conclusionNT-proBNP is a novel independent marker of mortality in HIV-infected women both when HAART was first introduced and currently. As NT-proBNP is often associated with both pulmonary hypertension and left ventricular dysfunction, these findings suggest that these conditions may contribute significantly to adverse outcomes in this population, requiring further definition of causes and treatments of elevated NT-proBNP in HIV-infected women.

Indexed as

AdultAntiretroviral Therapy, Highly ActiveCause of DeathCohort StudiesFemaleHIV InfectionsHumansMortalityNatriuretic Peptide, BrainPeptide FragmentsPrognosisRisk FactorsSex FactorsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID25811188
PMCPMC4374715
OpenAlexW1997793071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.